Tricyclics and newer antidepressant medications

Treatment options for treatment-resistant depressions

M. E. Thase, A. J. Rush, S. Kasper, Charles Nemeroff

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Only about 60-70% of those depressed patients who can tolerate an antidepressant medication, and only about 50-60% of those who begin a medication will respond to the first trial. Furthermore, 5-10% will remain depressed despite multiple medication trials. When the disorder is poorly responsive, it is variously described as a resistant, refractory, or intractable depression. This review summarizes the available literature on treatment-resistant depression (TRD) to provide recommendations for the most rational alternative strategies.

Original languageEnglish
Pages (from-to)152-168
Number of pages17
JournalDepression
Volume2
Issue number3
StatePublished - Dec 1 1994
Externally publishedYes

Fingerprint

Treatment-Resistant Depressive Disorder
Tricyclic Antidepressive Agents
Antidepressive Agents
Depression
Therapeutics

Keywords

  • Augmentation strategies
  • Heterocyclic antidepressants
  • Monoamine oxidase inhibitors
  • Selective serotonin reuptake inhibitors
  • Treatment-resistant depression
  • Tricyclic antidepressants

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Tricyclics and newer antidepressant medications : Treatment options for treatment-resistant depressions. / Thase, M. E.; Rush, A. J.; Kasper, S.; Nemeroff, Charles.

In: Depression, Vol. 2, No. 3, 01.12.1994, p. 152-168.

Research output: Contribution to journalArticle

@article{f3971a4155df4e6a822d4226190b8d84,
title = "Tricyclics and newer antidepressant medications: Treatment options for treatment-resistant depressions",
abstract = "Only about 60-70{\%} of those depressed patients who can tolerate an antidepressant medication, and only about 50-60{\%} of those who begin a medication will respond to the first trial. Furthermore, 5-10{\%} will remain depressed despite multiple medication trials. When the disorder is poorly responsive, it is variously described as a resistant, refractory, or intractable depression. This review summarizes the available literature on treatment-resistant depression (TRD) to provide recommendations for the most rational alternative strategies.",
keywords = "Augmentation strategies, Heterocyclic antidepressants, Monoamine oxidase inhibitors, Selective serotonin reuptake inhibitors, Treatment-resistant depression, Tricyclic antidepressants",
author = "Thase, {M. E.} and Rush, {A. J.} and S. Kasper and Charles Nemeroff",
year = "1994",
month = "12",
day = "1",
language = "English",
volume = "2",
pages = "152--168",
journal = "Depression",
issn = "1062-6417",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Tricyclics and newer antidepressant medications

T2 - Treatment options for treatment-resistant depressions

AU - Thase, M. E.

AU - Rush, A. J.

AU - Kasper, S.

AU - Nemeroff, Charles

PY - 1994/12/1

Y1 - 1994/12/1

N2 - Only about 60-70% of those depressed patients who can tolerate an antidepressant medication, and only about 50-60% of those who begin a medication will respond to the first trial. Furthermore, 5-10% will remain depressed despite multiple medication trials. When the disorder is poorly responsive, it is variously described as a resistant, refractory, or intractable depression. This review summarizes the available literature on treatment-resistant depression (TRD) to provide recommendations for the most rational alternative strategies.

AB - Only about 60-70% of those depressed patients who can tolerate an antidepressant medication, and only about 50-60% of those who begin a medication will respond to the first trial. Furthermore, 5-10% will remain depressed despite multiple medication trials. When the disorder is poorly responsive, it is variously described as a resistant, refractory, or intractable depression. This review summarizes the available literature on treatment-resistant depression (TRD) to provide recommendations for the most rational alternative strategies.

KW - Augmentation strategies

KW - Heterocyclic antidepressants

KW - Monoamine oxidase inhibitors

KW - Selective serotonin reuptake inhibitors

KW - Treatment-resistant depression

KW - Tricyclic antidepressants

UR - http://www.scopus.com/inward/record.url?scp=0028625408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028625408&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 152

EP - 168

JO - Depression

JF - Depression

SN - 1062-6417

IS - 3

ER -